From: HIV vaccine acceptability among high-risk drug users in Appalachia: a cross-sectional study
Characteristic | Vaccine acceptability | Bivariate | ||
---|---|---|---|---|
Not very likelya(n = 176) | Very likely (n = 257) | OR (95% CI) | p-value | |
Demographic | ||||
Male | 122 (69.3) | 117 (45.5) | 0.24 (0.12- 0.48) | <0.001** |
White | 163 (92.6) | 244 (94.9) | 2.16 (0.68 – 6.90) | 0.194 |
Age - mean (SD) | 36.3 (9.3) | 34.9 (8.1) | 0.96 (0.94 – 0.99) | 0.018* |
Income (n = 432) - mean (SD) | $908 (1473) | $913 (1125) | 1.00 (1.00 - 1.00) | 0.629 |
High school graduate | 93 (52.8) | 158 (61.5) | 1.63 (0.93 – 2.85) | 0.088 |
Uninsured | 114 (64.8) | 171 (66.5) | 1.32 (0.76 – 2.30) | 0.331 |
Married | 41 (23.3) | 70 (27.2) | 1.58 (0.85 – 2.93) | 0.144 |
Behavioral (past 6 months) | ||||
Injected drugs | 46 (26.1) | 100 (38.9) | 2.54 (1.41 – 4.58) | 0.002** |
Injected with unclean needle | 9 (5.1) | 24 (9.3) | 4.53 (1.53 – 13.39) | 0.006** |
Distributed unclean needleb | 5 (2.8) | 11 (4.3) | 3.23 (0.72 – 14.38) | 0.125 |
Shared injection equipmentc | 18 (10.2) | 37 (14.4) | 2.02 (0.90 – 4.55) | 0.090 |
Had multiple sex partners | 35 (19.9) | 68 (26.5) | 1.53 (0.78 – 2.98) | 0.213 |
Had unprotected sex | 120 (68.2) | 188 (73.2) | 1.49 (0.68 – 2.66) | 0.180 |
Unprotected sex with PWID | 24 (13.6) | 61 (23.7) | 3.33 (1.64 – 6.76) | 0.001** |
Attitudes about HIV | ||||
Severity of HIV | 173 (98.3) | 254 (98.8) | 1.53 (0.13 – 18.25) | 0.738 |
Susceptibility to HIV | 23 (13.1) | 77 (30.0) | 4.63 (2.17 – 9.90) | <0.001** |
Benefits of HIV vaccine | 103 (58.5) | 210 (81.7) | 5.85 (2.76 – 12.40) | <0.001** |
Barriers to HIV vaccination | 149 (84.7) | 195 (75.9) | 0.52 (0.26 – 1.03) | 0.060 |
Experiential attitude | 127 (72.2) | 216 (84.0) | 3.14 (1.60 – 6.16) | 0.001** |
Subjective norms | ||||
Descriptive norms | 65 (37.1) | 130 (50.6) | 2.36 (1.34 – 4.18) | 0.003** |
Injunctive norms | 85 (48.6) | 166 (64.6) | 2.67 (1.47 – 11.13) | 0.001** |
Agency | ||||
Behavioral control | 101 (57.4) | 175 (68.1) | 1.88 (1.05 – 3.34) | 0.032* |
Self-efficacy | 26 (14.8) | 57 (22.2) | 2.01 (0.98 – 4.13) | 0.058 |